0K2H.LSE Moleculin Biotech, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0K2H.LSE undervalued?
Graham numberThe Graham number of Moleculin Biotech, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Moleculin Biotech, Inc. fundamental analysis
No fundamental analysis for Moleculin Biotech, Inc. yet.
Moleculin Biotech, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription mo…
Full company profileFinancial statements of Moleculin Biotech, Inc. are not available yet.
Moleculin Biotech, Inc. dividends
Moleculin Biotech, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 0.05:1 on Oct 20, 2026.
Who owns Moleculin Biotech, Inc.
- Insiders 7.18%
- Institutions 7.95%
- Public & others 84.88%
- Free float 839K
Moleculin Biotech, Inc. company profile
- Company name
- Moleculin Biotech, Inc.
- Ticker
- 0K2H.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 5300 Memorial Drive, Houston, TX, United States, 77007
- Phone
- 713 300 5160
- Website
- moleculin.com
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Moleculin Biotech, Inc. management
5- Mr. Walter V. KlempChairman, President & CEO · born 1960
- Mr. Jonathan P. Foster CPAExecutive VP & CFO · born 1964
- Dr. Donald H. Picker Ph.D.Chief Scientific Officer · born 1946
- Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
- Dr. John Paul Waymack M.D., Sc.D.Senior Chief Medical Officer · born 1952